enGene Holdings Inc. (NASDAQ:ENGNW) Sees Significant Decline in Short Interest

enGene Holdings Inc. (NASDAQ:ENGNW) was the recipient of a significant drop in short interest in June. As of June 30th, there was short interest totalling 700 shares, a drop of 53.3% from the June 15th total of 1,500 shares. Based on an average trading volume of 6,400 shares, the days-to-cover ratio is currently 0.1 days.

enGene Trading Up 5.3 %

Shares of NASDAQ:ENGNW traded up $0.06 during trading on Friday, reaching $1.20. 350 shares of the stock traded hands, compared to its average volume of 26,917. enGene has a 52-week low of $0.39 and a 52-week high of $6.50. The stock has a 50-day moving average of $2.35 and a two-hundred day moving average of $2.80.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.